Literature DB >> 18840133

Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia.

C J Buskens1, F J W Ten Kate, H Obertop, J R Izbicki, J J B van Lanschot.   

Abstract

SUMMARY: Lymphatic dissemination is the most important prognostic factor in patients with esophageal carcinoma. However, the clinical significance of lymph node micrometastases is still debated due to contradictory results. The aim of the present study was to identify the incidence of potentially relevant micrometastatic disease in patients with histologically node-negative esophageal adenocarcinoma and to analyze the sensitivity and specificity of three different immunohistochemical assays. From a consecutive series of 79 patients who underwent a transthoracic resection with extended 2-field lymphadenectomy, all 20 patients with pN0 esophageal adenocarcinoma were included in this study. A total of 578 lymph nodes were examined for the presence of micrometastases by immunohistochemical analysis with the antibodies Ber-EP4, AE1/AE3 and CAM 5.2. Lymph node micrometastases were detected in five of the 20 patients (25%). They were identified in 16 of the 578 lymph nodes examined (2.8%) and most frequently detected with the Ber-EP4 and AE1/AE3 antibody (sensitivity 95% and 79% respectively). In 114 of the 559 negative lymph nodes (20.4%), positive single cells were found that did not demonstrate malignant characteristics. These false-positive cells were more frequently found with the AE1/AE3 staining (specificity of the Ber-Ep4 and AE1/AE3 antibody 94% and 84% respectively). The presence of nodal micrometastases was associated with the development of locoregional recurrences (P=0.01), distant metastases (P=0.01), and a reduced overall survival (log rank test, P=0.009). For the detection of clinically relevant micrometastatic disease in patients operated upon for adenocarcinoma of the distal esophagus or gastric cardia, Ber-EP4 is the antibody of first choice because of its high sensitivity and specificity. Immunohistochemically detected micrometastases in histologically negative lymph nodes have potential prognostic significance and are associated with a high incidence of both locoregional and systemic recurrence. Therefore, this technique has the potential to refine the staging system for esophageal cancer and to help identify patients who will not be cured by surgery alone.

Entities:  

Mesh:

Year:  2008        PMID: 18840133     DOI: 10.1111/j.1442-2050.2007.00805.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  4 in total

1.  The Number of Harvested LNs Is an Independent Prognostic Factor in Lymph Node Metastasis-negative Patients Who Received Curative Esophagectomy.

Authors:  Toru Aoyama; Yosuke Atsumi; Shinnosuke Kawahara; Hiroshi Tamagawa; Ayako Tamagawa; Yukio Maezawa; Kazuki Kano; Masaaki Murakawa; Keisuke Kazama; Masakatsu Numata; Takashi Oshima; Norio Yukawa; Munetaka Masuda; Yasushi Rino
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Occult Tumour Cells in Lymph Nodes from Gastric Cancer Patients: Should Isolated Tumour Cells Also Be Considered?

Authors:  A Tavares; X Wen; J Maciel; F Carneiro; M Dinis-Ribeiro
Journal:  Ann Surg Oncol       Date:  2020-05-04       Impact factor: 5.344

Review 3.  Lymph Node Metastases in Esophageal Carcinoma: An Endoscopist's View.

Authors:  Jin Woong Cho; Suck Chei Choi; Jae Young Jang; Sung Kwan Shin; Kee Don Choi; Jun Haeng Lee; Sang Gyun Kim; Jae Kyu Sung; Seong Woo Jeon; Il Ju Choi; Gwang Ha Kim; Sam Ryong Jee; Wan Sik Lee; Hwoon-Yong Jung
Journal:  Clin Endosc       Date:  2014-11-30

4.  Lymph Node and Bone Marrow Micrometastases Define the Prognosis of Patients with pN0 Esophageal Cancer.

Authors:  Karl-F Karstens; Tarik Ghadban; Katharina Effenberger; Guido Sauter; Klaus Pantel; Jakob R Izbicki; Yogesh Vashist; Alexandra König; Matthias Reeh
Journal:  Cancers (Basel)       Date:  2020-03-04       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.